Stockscreener 앱 받기
1.92
4.48%
-0.09
시간 외 거래:
1.91
-0.01
-0.52%
Genprex Inc 주식(GNPX)의 최신 뉴스
Genprex collaborators to present lung cancer data at AACR meeting By Investing.com - Investing.com South Africa
Genprex presents positive preclinical REQORSA data at AACR showing biomarkers and combo efficacy - TradingView
Genprex Highlights New Reqorsa Preclinical Data at AACR - TipRanks
GNPX: Genprex Researchers to Present at AACR 2026 with Promising Lung Cancer Data - GuruFocus
Genprex collaborators to present lung cancer data at AACR meeting - Investing.com
Genprex (NASDAQ: GNPX) posts positive preclinical data on REQORSA in NSCLC - Stock Titan
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - PR Newswire
New Highs: Will Genprex Inc benefit from green energy policiesTrade Risk Assessment & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill
Genprex to Participate at BIO Europe Spring 2026 - Barchart
GNPX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Closing: Will Genprex Inc outperform tech stocksMarket Activity Report & Weekly High Return Forecasts - baoquankhu1.vn
Trend Recap: Will Genprex Inc outperform tech stocksWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Genprex receives patent approval in Australia for cancer therapy - Investing.com Nigeria
GNPX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Genprex (NASDAQ: GNPX) CMO has shares withheld to cover RSU taxes - Stock Titan
Genprex (GNPX) CEO reports 9,330-share tax-withholding disposition - Stock Titan
Congressional Trading Activity Insights - Intellectia AI
Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy - Indian Pharma Post
Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying - Benzinga
Genprex Advances Cancer Therapy Strategy with Key International Patents - AD HOC NEWS
Genprex receives Japanese and European patents for cancer therapy By Investing.com - Investing.com India
Genprex stock jumps on Japan, Europe patent approvals By Investing.com - Investing.com Nigeria
Genprex stock jumps on Japan, Europe patent approvals - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Genprex (GNPX) Gains Global Patent Approvals for Innovative Canc - GuruFocus
Genprex Secures Key Global Patents for REQORSA Therapy - TipRanks
Genprex receives Japanese and European patents for cancer therapy - Investing.com
Genprex secures Japan, EU patents for REQORSA combos, bolstering Acclaim-3 IP and trial - TradingView
New cancer patents support Genprex (NASDAQ: GNPX) Acclaim-3 trial - Stock Titan
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - Barchart.com
Genprex Navigates a Pivotal Juncture Amid Clinical Progress and Financial Strain - AD HOC NEWS
Published on: 2026-02-21 03:40:37 - baoquankhu1.vn
Will Genprex Inc. benefit from green energy policiesChart Signals & Accurate Trade Setup Notifications - mfd.ru
How strong is Genprex Inc. (2DE0) stock earnings growth2025 Short Interest & Precise Swing Trade Entry Alerts - mfd.ru
Genprex receives patent approval in Australia for cancer therapy By Investing.com - Investing.com Canada
Ayrton Capital-led group reports 9.72% Genprex (GNPX) stake via warrants - Stock Titan
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - BioSpace
Genprex (GNPX) Gains Australian Patent Approval for Cancer Treat - GuruFocus
Genprex Gains Australian Patent Acceptance for REQORSA Therapy - TipRanks
Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy - TradingView
Genprex Patent Acceptance and Clinical Trial Expansion - TradingView
Genprex (NASDAQ: GNPX) advances REQORSA patent strategy and expands Acclaim-3 lung cancer trial - Stock Titan
Bull Run: Will Genprex Inc benefit from green energy policiesPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Genprex Shares Seek Catalysts Amid Clinical Trial Focus - AD HOC NEWS
Institution Moves: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEARExit Point & Short-Term Trading Alerts - baoquankhu1.vn
Aug PreEarnings: Will Genprex Inc outperform tech stocksShort Setup & Safe Entry Point Identification - baoquankhu1.vn
Aug Patterns: Whats the outlook for TMD Energy Limiteds sectorWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative
Aug Spikes: How does Genprex Inc score in quality rankingsFed Meeting & High Accuracy Investment Signals - baoquankhu1.vn
Take Profit: Is Genprex Inc stock a defensive play in 20252025 Sector Review & Verified Stock Trade Ideas - Bộ Nội Vụ
Genprex Regains Nasdaq Compliance but Faces Ongoing Monitoring - The Globe and Mail
MSN Money - MSN
Genprex Regains Nasdaq Compliance - TradingView — Track All Markets
1.20%
0.06%
자본화:
|
볼륨(24시간):